What was approved and why it matters
AbbVie's lutikizumab is an antibody that blocks both IL-1 alpha and IL-1 beta. In the Phase III INTREPID trial in moderate to severe hidradenitis suppurativa it met its primary endpoint with a safety profile similar to placebo.
Frequently asked questions
What did the INTREPID trial show?
31.4% of patients on lutikizumab reached HiSCR75 at week 16 against 23.4% on placebo. Pain improved faster and fewer patients had flares; adverse event rates matched placebo.
When could lutikizumab be approved?
AbbVie plans regulatory submissions in the second half of 2027, after 52 week data.
What are lutikizumab's projected sales?
Zaash Labs' base case is about USD 450 million of US net revenue in 2032, within a range of USD 225 million to 800 million.
Figures are company reported or from published sources unless marked as Zaash Labs estimates. Sources are listed in the executive summary and the full report. Market research to support business decisions; not investment advice.